以维奈克拉为基础的挽救治疗用于急性髓系白血病造血细胞移植后复发
该研究报告21例因髓系疾病接受异基因造血细胞移植后复发为急性髓系白血病并接受维奈克拉为基础治疗的患者结局。中位年龄64.5岁,移植至复发中位时间5.7个月。可评估疗效的19例中8例有意义的治疗反应:5例完全缓解、3例完全缓解伴血细胞计数不完全恢复、0例部分缓解,总反应率42.1%。
要点
- 移植后复发为急性髓系白血病的21例患者接受维奈克拉为基础治疗,中位年龄64.5岁。
- 可评估的19例中总反应率42.1%,包括5例完全缓解和3例完全缓解伴血细胞计数不完全恢复。
- 9例维持反应≥3个月,8例在数据截止时仍在接受治疗。
核心结论
- 移植后急性髓系白血病复发结局极差,以维奈克拉为基础的治疗是有效的治疗选择,应在此背景下开展前瞻性研究。
研究设计与样本
- 报告21例因髓系疾病接受异基因造血细胞移植后复发为急性髓系白血病并接受维奈克拉为基础治疗的患者结局。
主要发现
- 中位年龄64.5岁,移植至复发中位时间5.7个月(范围0.9至44.9个月)。
- 可评估疗效的19例中,5例完全缓解、3例完全缓解伴血细胞计数不完全恢复、0例部分缓解,总反应率42.1%。
- 另有6例观察到治疗效应,其中4例处于形态学无白血病状态。
- 9例维持反应≥3个月,8例在数据截止时仍在接受治疗。
关键数值与推荐
- 可评估疗效的19例中,总反应率42.1%。
- 21例中,既往血液系统恶性肿瘤6例、复杂核型6例、TP53突变5例。
临床怎么用
- 作者认为以维奈克拉为基础的治疗是移植后急性髓系白血病复发的有效治疗选择,应在此背景下开展前瞻性研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For patients with high risk myeloid disease, allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy. Unfortunately, many of these patients relapse after HCT and have a limited survival. The recent approval of venetoclax, an orally bioavailable BCL-2 inhibitor, resulted in significant responses in treatment naïve acute myeloid leukemia (AML), and off-label use in the relapsed/refractory setting is increasing. We report the outcomes of 21 patients who underwent allogeneic HCT for myeloid disease, relapsed with AML, and were treated with venetoclax. Several patients had poor risk features including antecedent hematologic malignancy (6/21), complex karyotype (6/21), and TP53 mutations (5/21). The median age was 64.5 years and time from HCT to relapse was 5.7 months (range: 0.9 to 44.9 months). Of the 19 patients who were assessed for response, there were meaningful treatment responses seen in eight patients: five CR, three CRi, zero PR, for an ORR of 42.1%. Treatment effect was seen in six additional patients, including four in the morphologic leukemia-free state. Nine patients maintained their response for ≥3 months and eight were receiving therapy at data cut. Post-HCT AML relapse has an exceedingly poor outcome, and venetoclax-based therapy is a potent therapy option that should be studied prospectively in this setting.
引用
- Byrne M, Danielson N, Sengsayadeth S, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am J Hematol. 2020. PMID: 32390196. doi:10.1002/ajh.25859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。